Sellas Life Sciences' Potential Leukemia Treatment Receives Second Rare Pediatric Disease Designation
Sellas Life Sciences' Potential Leukemia Treatment Receives Second Rare Pediatric Disease Designation
sellas life sciences的潜在白血病治疗方案获得第二个罕见儿童疾病认证。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册